The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Nov. 27, 8:00 AM

Slide #24. Receptos Secondary Offering

Company: Receptos (NASDAQ:RCPT)
Date announced: 11/17/2014
Shares Offered: 3,600,000
Date of Pricing: 11/18/2014
Price Per Share: $100.00
Secondary Offering Details: Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Receptos. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. - updated 11/19 - Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $100.00 per share. The gross proceeds to Receptos from this offering are expected to be $360 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares of common stock to be sold in the offering are being offered by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an additional 540,000 shares of common stock. The offering is expected to close on or about November 24, 2014, subject to customary closing conditions.

Receptos is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics for immune disorders. Co.'s key product candidate, RPC1063, is being developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis, an autoimmune disorder of the central nervous system, and Inflammatory Bowel Disease, which is comprised of two autoimmune, gastrointestinal inflammatory disorders: Ulcerative Colitis and Crohn's Disease. Co.'s other product candidate, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, Eosinophilic Esophagitis, an immune-mediated Orphan Disease with symptoms related to esophageal dysfunction.
Open the RCPT Page at The Online Investor »

Company Name:  Receptos, Inc.
Website:  www.receptos.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding RCPT:  19
Total Market Value Held by ETFs:  $106.76M
Total Market Capitalization:  $3.46B
% of Market Cap. Held by ETFs:  3.08%
 

Open the RCPT Page at The Online Investor (in a new window) »

November 27, 2014    8:00 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
90th percentile
(ranked higher than approx. 90% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.